NASDAQ:RPTP - Raptor Pharmaceutical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$9.00
Today's Range$9.00 - $9.00
52-Week Range$2.94 - $9.05
VolumeN/A
Average Volume1.42 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), is indicated as an orphan medicinal product for the management of nephropathic cystinosis. Its QUINSAIR is a formulation of the antibiotic drug levofloxacin, suitable for inhalation via a nebulizer. It is engaged in developing MP-376 for non-CF bronchiectasis (BE) and nontuberculous mycobacteria (NTM) lung infections. It is also engaged in developing RP105 and RP106 for various diseases.

Receive RPTP News and Ratings via Email

Sign-up to receive the latest news and ratings for RPTP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:RPTP
Previous Symbol
CUSIP75382F10
Phone+1-415-4086200

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees158
Outstanding SharesN/A
Market Cap$0.00
OptionableOptionable

Raptor Pharmaceutical (NASDAQ:RPTP) Frequently Asked Questions

What is Raptor Pharmaceutical's stock symbol?

Raptor Pharmaceutical trades on the NASDAQ under the ticker symbol "RPTP."

Has Raptor Pharmaceutical been receiving favorable news coverage?

News headlines about RPTP stock have been trending somewhat negative on Wednesday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Raptor Pharmaceutical earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Raptor Pharmaceutical?

Shares of RPTP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Raptor Pharmaceutical's official website?

The official website for Raptor Pharmaceutical is http://www.horizonpharma.com/.

How can I contact Raptor Pharmaceutical?

Raptor Pharmaceutical's mailing address is 7 Hamilton Lndg Ste 100, NOVATO, CA 94949-8283, United States. The biotechnology company can be reached via phone at +1-415-4086200.


MarketBeat Community Rating for Raptor Pharmaceutical (NASDAQ RPTP)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  243 (Vote Underperform)
Total Votes:  469
MarketBeat's community ratings are surveys of what our community members think about Raptor Pharmaceutical and other stocks. Vote "Outperform" if you believe RPTP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RPTP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by MarketBeat.com Staff

Featured Article: Insider Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel